# A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

> **NCT06526624** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 406 (estimated)

## Conditions studied

- Limited-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** HS-20093

## Key facts

- **NCT ID:** NCT06526624
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2027-11-30
- **Final completion:** 2029-01-31
- **Target enrollment:** 406 (ESTIMATED)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06526624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06526624, "A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06526624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*